ImmunityBio Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Public

  • Employees
  • 628

Employees

  • Stock Symbol
  • IBRX

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $5.96
  • (As of Tuesday Closing)

ImmunityBio General Information

Description

ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

Contact Information

Formerly Known As
NantCell, NantBioCell, Conkwest, Inc., Zellerx Corp
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Corporate Office
  • 3530 John Hopkins Court
  • San Diego, CA 92121
  • United States
+1 (844) 000-0000

ImmunityBio Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ImmunityBio Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$5.96 $6.24 $1.25 - $10.53 $4.12B 677M 7.11M -$1.09

ImmunityBio Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 4,096,819 3,880,423 2,628,083 2,676,511
Revenue 302 622 240 934
EBITDA (446,923) (437,045) (338,219) (321,588)
Net Income (600,962) (583,196) (416,567) (346,790)
Total Assets 400,679 504,452 362,356 468,910
Total Debt 731,367 726,723 723,773 645,664
Public Fundamental Data provided by Morningstar, Inc. disclaimer

ImmunityBio Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore ImmunityBio‘s full profile, request access.

Request a free trial

ImmunityBio Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-
Biotechnology
San Diego, CA
628 As of 2023
00000
000000000 00000

0000 0

ip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate
0000 000000000
Cambridge, MA
00 As of 0000
00000
00000000 00000

000000

quat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolo
0000 000000000
Seattle, WA
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ImmunityBio Competitors (65)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Formerly VC-backed Cambridge, MA 00 00000 00000000 00000
Immusoft Venture Capital-Backed Seattle, WA 00 000.00 0000000000 0 000.00
CytomX Therapeutics Formerly VC-backed South San Francisco, CA 000 00000 00000000 00000
Adicet Bio Formerly VC-backed Boston, MA 000 00000 00000000 00000
Iovance Biotherapeutics Corporation San Carlos, CA 000 00000 00000000 00000
You’re viewing 5 of 65 competitors. Get the full list »

ImmunityBio Patents

ImmunityBio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20240156934-A1 Compositions and methods of mait cell activation Pending 15-Nov-2022 000000000000
EP-4335870-A1 Peptide therapeutics against sars-cov-2 spike protein Pending 06-Sep-2022 00
US-20240029820-A1 Computing affinity for protein-protein interaction Pending 22-Jul-2022 000000000
US-20230381313-A1 Cd16high cd57high nk-92mi cells Pending 24-May-2022 00000000000
US-20230368377-A1 Systems and methods of analyzing microbiomes using artificial intelligence Pending 13-May-2022 G06T7/0012
To view ImmunityBio’s complete patent history, request access »

ImmunityBio Executive Team (13)

Name Title Board Seat Contact Info
Richard Adcock Chief Executive Officer, Board Member & President
David Sachs Chief Financial Officer, Finance
Leonard Sender Chief Operating Officer
Enrique Diloné Ph.D Chief Technology Officer
Regan Lauer Chief Accounting Officer, Accounting
You’re viewing 5 of 13 executive team members. Get the full list »

ImmunityBio Board Members (8)

Name Representing Role Since
Barry Simon MD ImmunityBio Chief Corporate Affairs Officer 000 0000
Cheryl Cohen Self Board Member 000 0000
Christobel Selecky Self Board Member 000 0000
Linda Maxwell MD ImmunityBio Board Member 000 0000
Michael Blaszyk Self Board Member 000 0000
You’re viewing 5 of 8 board members. Get the full list »

ImmunityBio Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ImmunityBio Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore ImmunityBio‘s full profile, request access.

Request a free trial

ImmunityBio Investments & Acquisitions (8)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Joint Venture (Amyris / ImmunityBio) 03-Jan-2022 00000 0000 Pharmaceuticals
NantKwest 09-Mar-2021 0000000000 Drug Discovery 0000000 0
Altor BioScience 01-Aug-2017 0000000000 000 Drug Discovery 0000000 0
Liquid Genomics 31-Mar-2017 0000000000 00.000 Biotechnology
GlobeImmune 23-Mar-2017 Merger/Acquisition 00.00 Biotechnology 0000000 0
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

ImmunityBio Subsidiaries (1)

Company Name Industry Location Founded
GlobeImmune Biotechnology Louisville, CO 0000
To view ImmunityBio’s complete subsidiaries history, request access »

ImmunityBio ESG

Risk Overview

Risk Rating

Updated December, 06, 2022

34.27 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.00

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Pharmaceuticals

Subindustry

00 of 452

Rank

00.00

Percentile

To view ImmunityBio’s complete esg history, request access »

ImmunityBio FAQs

  • When was ImmunityBio founded?

    ImmunityBio was founded in 2014.

  • Who is the founder of ImmunityBio?

    Patrick Soon-Shiong MD is the founder of ImmunityBio.

  • Who is the CEO of ImmunityBio?

    Richard Adcock is the CEO of ImmunityBio.

  • Where is ImmunityBio headquartered?

    ImmunityBio is headquartered in San Diego, CA.

  • What is the size of ImmunityBio?

    ImmunityBio has 628 total employees.

  • What industry is ImmunityBio in?

    ImmunityBio’s primary industry is Biotechnology.

  • Is ImmunityBio a private or public company?

    ImmunityBio is a Public company.

  • What is ImmunityBio’s stock symbol?

    The ticker symbol for ImmunityBio is IBRX.

  • What is the current stock price of ImmunityBio?

    As of 11-Jun-2024 the stock price of ImmunityBio is $5.96.

  • What is the current market cap of ImmunityBio?

    The current market capitalization of ImmunityBio is $4.12B.

  • What is ImmunityBio’s current revenue?

    The trailing twelve month revenue for ImmunityBio is $302K.

  • Who are ImmunityBio’s competitors?

    Aura Biosciences, Immusoft, CytomX Therapeutics, Adicet Bio, and Iovance Biotherapeutics are some of the 65 competitors of ImmunityBio.

  • What is ImmunityBio’s annual earnings per share (EPS)?

    ImmunityBio’s EPS for 12 months was -$1.09.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »